Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
Harvard Medical School, Boston, MA, 02115, USA.
Genome Med. 2018 Nov 22;10(1):87. doi: 10.1186/s13073-018-0598-2.
Immunotherapy has revolutionized the management of numerous cancers; however, a substantial proportion that initially respond subsequently acquire means of immune escape and relapse. Analysis of recent clinical trials permits us to preliminarily understand how immunotherapies exert evolutionary pressures: selecting cancer subclones deficient in antigenicity and/or immunogenicity, thereby facilitating immune escape.
免疫疗法已经彻底改变了多种癌症的治疗方式；然而，相当一部分最初有反应的癌症随后会获得免疫逃逸和复发的手段。对最近临床试验的分析使我们能够初步了解免疫疗法如何施加进化压力：选择抗原性和/或免疫原性缺陷的癌症亚克隆，从而促进免疫逃逸。
